NR1H4 and metabolic disease: Oral administration of FXR antagonists tauro-β-muricholate (T-βMCA) and glycine-β-muricholate (Gly-MCA) prevented or reversed HFD-induced and genetic obesity and metabolic disorder based on reduced biosynthesis of intestinal-derived ceramides [33].